NKTR — NEKTAR THERAPEUTICS
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 906709 ·
Last close
$41.17
Market Cap
$1.41B
52W High
$109.00
52W Low
$33.40
ADV30
1,566,503
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 10,131,000 | — | — | -40,622,000 | — | 39,267,000 | — |
| Mar 2026 | 10,861,000 | — | -38,258,000 | -44,904,000 | 763,271,000 | 149,578,000 | 187,055,000 |
| Dec 2025 | 21,807,000 | 21,807,000 | -19,090,000 | -36,079,000 | 280,406,000 | 15,116,000 | 190,574,000 |
| Sep 2025 | 11,790,000 | 11,790,000 | -31,532,000 | -35,522,000 | 301,347,000 | 41,032,000 | 216,261,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-203,756,000
Investing CF
$-395,675,000
Financing CF
$710,108,000
CapEx
$-187,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-8.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,805,190,000
Inventory
$0
Receivables
$3,600,000
ST Investments
$419,026,000
EBIT TTM
$-123,056,000
Pretax Income TTM
$-152,208,000
Interest Exp TTM
$29,152,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,589,000
EBITDA
$-129,950,000
Free Cash Flow
$-134,766,368
Enterprise Value
$1,833,408,256
Total Cash
$684,340,992
Total Debt
$135,934,000
Shares Out
34,142,994
Trailing EPS
$-6.12
Book Value
$26.46
ROE
-35.8%
ROA
-12.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 55,232,000 | -130,771,000 | -164,076,000 | 280,406,000 | 190,574,000 | 89,832,000 | -208,511,000 |
| Dec 2024 | 98,427,000 | -129,918,000 | -118,961,000 | 303,850,000 | 243,113,000 | 60,737,000 | -175,709,000 |
| Dec 2023 | 90,122,000 | -135,225,000 | -276,056,000 | 398,033,000 | 267,046,000 | 130,987,000 | -192,606,000 |
| Dec 2022 | 92,055,000 | -240,236,000 | -368,198,000 | 710,600,000 | 343,962,000 | 366,638,000 | -304,007,000 |
TTM Snapshot
Revenues TTM
$55,633,000
NetIncome TTM
$-158,098,000
OpCashFlow TTM
—
Assets (Latest)
$763,271,000
Forward EPS
$-10.84
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.38B | $14.75 | — |
| OMER | OMEROS CORP | $1.44B | $19.83 | — |
| KARD | Kardigan, Inc. | $1.37B | $14.67 | — |
| PCRX | Pacira BioSciences, Inc. | $1.45B | $36.31 | — |
| GHRS | GH Research PLC | $1.45B | $21.11 | — |
News headlines (Yahoo Finance, 1h cache)
Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
2026-10-07 15:33 · Yahoo
EADV26: Key late-stage readouts from the conference
2026-10-05 11:57 · Yahoo
Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.
2026-10-01 20:29 · Yahoo
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
2026-10-01 19:42 · Yahoo
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
2026-10-01 16:23 · Yahoo
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
2026-10-01 16:02 · Yahoo
3 Biotech Stocks Put Traders Are Targeting Today
2026-10-01 15:44 · Yahoo
/UPDATE -- Nektar Therapeutics/
2026-10-01 13:43 · Yahoo
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
2026-09-30 14:30 · Yahoo
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors
2026-09-30 04:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.